BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Everett Laboratories Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.


5/23/2012 12:11:48 PM

WEST ORANGE, N.J., May 23, 2012 /PRNewswire/ -- Everett Laboratories, Inc., Women's Health Care company, leader in the field of prenatal supplementation, today announced that it had filed a patent infringement lawsuit with a motion for a preliminary injunction in the United States District Court of New Jersey against Trigen Laboratories, Inc., a specialty niche pharmaceutical company. The lawsuit asserts, among other things, that Trigen is infringing United States Patent No. 8,183,227 covering Everett's Vitafol®-One product, and seeks to prevent Trigen from making, selling, distributing and falsely branding its infringing, copycat products. Everett's lawsuit alleges that it will be irreparably harmed unless the court issues a preliminary injunction that requires Trigen immediately to withdraw its patent-infringing products from the market.

"We are fully committed to our innovation and to providing physicians and their patients with quality products for prenatal supplementation," said Lucas Sigman, Everett's Chief Executive Officer. "Our prenatal supplementation portfolio represents one of the Company's most valuable assets, and provides significant market and competitive advantages. We will not tolerate infringement of our patents, and we will do what is necessary to protect our proprietary rights."

Everett's lawsuit also alleges that Trigen's copycat products contain fish oil while Everett DHA is made from Algae oil. "We are committed to providing pregnant women with the highest-quality prenatal supplementation. That is our number one priority," said Louis Bongiovanni, Everett's Vice President of Sales.

About Everett Laboratories, Inc.

Everett Laboratories is a New Jersey-based women's healthcare pharmaceutical company that has been providing essential pharmaceutical and nutritional products for four decades. Everett is a subsidiary of The Chemo Group, a global healthcare corporation based in Spain with a presence in more than 30 countries. The company recently licensed products for stress urinary incontinence, fertility, and the Stuart Natal line of pre-natal vitamins. Everett is dedicated to providing advanced treatments and innovative new products to address unmet needs for women and families and to improving women's health. The company strives to produce and market unique, first-in-class prescription and over the counter medications.

SOURCE Everett Laboratories, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES